Japanese firm Torii Pharmaceutical Co. Ltd. and parent Japan Tobacco Inc. (JT) are planning a marketing authorization filing in Japan for their oral inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PH), following positive results in comparative Phase III trials.
The new top-line results came from two pivotal studies conducted in Japan with enarodustat (JTZ-951) in either anemic patients with non-dialysis-dependent chronic kidney disease (CKD) or with hemodialysis-dependent CKD and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?